Found vs Sequence Weight Loss (2026)

Found and Sequence both operate as clinical weight loss telehealth programs with GLP-1 access. They are not direct competitors in strategy — Found differentiates on medication matching (prescribing the right drug for each patient), while Sequence differentiates on insurance access (getting the right drug covered). For some patients, the ideal answer involves using both capabilities.

---

Quick Comparison

	Found	Sequence (Noom Sequence)
Monthly cost	~$99–199/month	~$99/month + copays
GLP-1 prescription	Yes — semaglutide, tirzepatide	Yes — semaglutide, tirzepatide
Non-GLP-1 medications	Yes — bupropion/naltrexone, topiramate, metformin, spironolactone	Limited — primarily GLP-1 focused
Insurance navigation	Yes (insurance team)	Yes — core differentiating feature
Compounded GLP-1	Yes (cash-pay)	Less emphasis; insurance-first approach
Coaching	App-based coaching	Health coach + dietitian access
Medication matching	Multi-medication algorithm	Standard GLP-1 protocol
PCOS/hormonal support	Spironolactone available	Less specialized
Provider visits	Async + scheduled	Video visits available

---

Found: The Multi-Medication Platform

Found's clinical differentiation is prescription matching — rather than defaulting everyone to GLP-1, Found's algorithm and medical team identify the medication most likely to work for each patient's metabolic profile:

• GLP-1 agonists — semaglutide, tirzepatide (appetite, metabolic reset)
• Bupropion/naltrexone (Contrave) — reward-pathway and cravings-driven eating
• Topiramate — specific eating pattern profiles; often combined
• Metformin — insulin resistance; foundational metabolic optimization
• Spironolactone — PCOS-related weight and androgen management (women only)

This breadth is clinically meaningful. Patients who fail GLP-1 because the primary driver is reward/craving eating (not hunger-driven eating) may do better on bupropion/naltrexone. Patients with PCOS benefit from spironolactone access in the same platform.

Found insurance navigation: Found has an insurance team that works to get medications covered. This is secondary to the clinical matching emphasis but is present.

---

Sequence: The Insurance Navigation Specialist

Sequence (acquired by Noom in 2023 and operated as part of the Noom platform) was built specifically to solve the GLP-1 access problem: patients who want semaglutide or tirzepatide but can't afford cash-pay prices.

Sequence's team works proactively with insurance companies to:

• Identify which GLP-1 medications are on your formulary
• Document the clinical case for prior authorization
• Appeal denials with supporting clinical documentation
• Navigate employer benefit GLP-1 coverage where available

The program fee is ~$99/month on top of insurance copays — which can be justified if it unlocks $800+/month brand-name GLP-1 coverage.

Sequence clinical approach: Once medication is secured, Sequence provides health coaching and dietitian access. The clinical care is solid but less differentiated than Found's multi-medication matching.

---

Insurance Navigation: How Each Performs

Scenario	Found	Sequence
GLP-1 covered by insurance	Insurance team navigates	Core specialty — deep navigation support
GLP-1 denied, appeal possible	Insurance team handles	Specialized appeal support
Employer benefit GLP-1 program	Can navigate	Optimized for this pathway
No insurance coverage	Compounded cash-pay available	Less emphasis; compounded is available
Complex prior authorization	Present but not specialist	Specialty capability

For patients with commercial insurance where GLP-1 coverage is possible, Sequence's specialized navigation is likely more effective than Found's generalist insurance team. For uninsured or cash-pay patients, Found's multi-medication matching is the differentiating value.

---

Clinical Outcomes

Program	Expected Weight Loss	Key Driver
Found (GLP-1)	~15–20%	GLP-1 mechanism
Found (bupropion/naltrexone)	~5–10%	Appetite + reward pathway
Found (combination)	~12–18%	Multi-mechanism
Sequence + GLP-1	~15–20%	GLP-1 mechanism

Both programs with GLP-1 produce equivalent outcomes — the medication is the primary driver. The differentiation is about whether you get the right medication and whether you pay cash vs insurance price.

---

Who Each Program Serves Best

Found is better if you:

• Are unsure which medication approach is right for your eating pattern
• Have failed GLP-1 before and want a different mechanism tried
• Have PCOS and need hormonal support alongside weight management
• Are paying cash and want the medication most likely to work for your biology
• Want a platform that prescribes beyond GLP-1

Sequence is better if you:

• Have commercial insurance and believe GLP-1 coverage may be accessible
• Have already been through a prior authorization denial and need appeal support
• Have employer benefits that may include GLP-1 coverage you haven't activated
• Want the most specialized insurance navigation available in telehealth
• Are primarily seeking brand-name GLP-1 at insurance pricing

---

Cost Analysis

Scenario	Found (Annual)	Sequence (Annual)
GLP-1 covered by insurance + $40 copay	~$1,788 (program) + $480 (copays) = $2,268	~$1,188 (program) + $480 (copays) = $1,668
GLP-1 cash-pay compounded	~$1,788 (program) + ~$1,800 (medication) = $3,588	~$1,188 (program) + ~$1,800 (medication) = $2,988
GLP-1 denied, non-GLP-1 medication	~$1,788 + $720 (bupropion) = **$2,500**	Less useful for non-GLP-1 pathway

If insurance coverage is achievable, Sequence's ~$600/year lower program fee compounds: over 2 years, the insurance navigation specialization saves ~$1,200 in program fees alone.

---

Related Resources

• Found Weight Loss Review — full review
• Sequence Weight Loss Review — full review
• Form Health vs Sequence — year-long clinical program vs insurance navigation
• GLP-1 Insurance Denial FAQ — how to appeal GLP-1 denials
• Best GLP-1 with Insurance Coverage — full ranking of insurance-navigation programs